Skip to main content

Table 3 Results of Cox proportional hazard regression analyses in mrEF

From: Differing effects of beta-blockers on long-term clinical outcomes following percutaneous coronary intervention between patients with mid-range and reduced left ventricular ejection fraction

  Univariable Multivariable
HR 95% CI p HR 95% CI p
Age: 1-year increase 1.04 1.02–1.06  < 0.001 1.03 1.01–1.05 0.007
Men: yes 0.70 0.44–1.17 0.164    
Hypertension: yes 1.18 0.78–1.83 0.438    
Diabetes Mellitus: yes 1.44 0.97–2.16 0.073 1.56 1.04–2.35 0.033
CKD (eGFR < 60 mL/min/1.73m2): yes 1.60 1.05–2.41 0.028 1.24 0.80–1.91 0.345
Family History of IHD: yes 0.73 0.44–1.18 0.204    
Current smoking: yes 0.60 0.35–0.97 0.037 0.81 0.47–1.40 0.435
LDL-C: 1 mg/dL increase 1.00 0.99–1.00 0.164    
HDL-C: 1 mg/dL increase 0.99 0.98–1.01 0.258    
LVEF: 1% increase 0.97 0.91–1.04 0.368    
Multivessel disease: yes 1.27 0.84–1.96 0.256    
Acute Coronary Syndrome: yes 1.19 0.79–1.77 0.407    
Statins use: yes 0.60 0.40–0.90 0.013 0.65 0.43–0.98 0.040
ACEIs/ARBs use: yes 1.12 0.73–1.78 0.609    
Aspirin use: yes 0.81 0.42–1.82 0.586    
Beta blocker use: yes 0.74 0.49–1.10 0.137    
  1. ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, CI confidence interval, CKD chronic kidney disease, eGFR estimated glomerular filtration rate, HDL-C high-density lipoprotein cholesterol, HR hazard ratio, IHD ischemic heart disease, LDL-C low-density lipoprotein cholesterol, LVEF left ventricular ejection fraction, mrEF mid-range ejection fraction